Clinical trial
Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)
NCT02577159 is registered in ClinicalTrials.gov with Osaka University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)
- Lead sponsor
- Osaka University
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- July 1, 2015
- Completion date
- August 31, 2018
- Enrollment
- 50 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.